← All trials
NCT07282054
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 13, 2022
- Primary completion
- Jan 23, 2025
- Completion date
- Jan 24, 2025
- First posted
- Dec 15, 2025
- Last posted
- Dec 15, 2025
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tonghua Dongbao Pharmaceutical Co.,LtdLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.